Graphite Bio, Inc. (GRPH)

NASDAQ: GRPH · IEX Real-Time Price · USD
3.50
+0.07 (2.04%)
Dec 2, 2022 4:00 PM EST - Market closed
2.04%
Market Cap 199.46M
Revenue (ttm) n/a
Net Income (ttm) -95.38M
Shares Out 55.21M
EPS (ttm) 5.18
PE Ratio 0.68
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 48,058
Open 3.43
Previous Close 3.43
Day's Range 3.3 - 3.54
52-Week Range 2.07 - 13.39
Beta n/a
Analysts Buy
Price Target 11.95 (+241.4%)
Earnings Date Nov 9, 2022

About GRPH

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency... [Read more]

Industry Biotechnology
IPO Date Jun 25, 2021
Employees 114
Stock Exchange NASDAQ
Ticker Symbol GRPH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for GRPH stock is "Buy." The 12-month stock price forecast is 11.95, which is an increase of 241.43% from the latest price.

Price Target
$11.95
(241.43% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to...

1 week ago - Business Wire

CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?

Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments moving through the pipeline toward FDA approval. The post CRISPR Stoc...

1 month ago - Investors Business Daily

Graphite Bio Announces Participation in 50th Annual Sickle Cell Disease Association of America National Convention

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $GRPH #GraphiteBio--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency pre...

1 month ago - Business Wire

Graphite Bio Announces Participation in Morgan Stanley 20th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to d...

2 months ago - Business Wire

Graphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $GRPH #GraphiteBio--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency pre...

3 months ago - Business Wire

Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $GRPH #GraphiteBio--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency pre...

3 months ago - Business Wire

BMO Capital Sees Over 400% Upside For This Small Gene-Editing Stock

BMO Capital Markets initiated coverage on Graphite Bio Inc (NASDAQ: GRPH), with a price target of $12 and an Outperform rating. The analyst notes that Graphite's gene editing approach involves a DNA rep...

5 months ago - Benzinga

Graphite Bio Announces Participation in Jefferies Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to d...

6 months ago - Business Wire

Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT 25th Annual Meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to d...

6 months ago - Business Wire

Graphite Bio Reports Recent Business Progress and First Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to d...

6 months ago - Business Wire

Graphite Bio Announces Participation in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to d...

7 months ago - Business Wire

Graphite Bio Announces U.S. FDA Fast Track Designation Granted to GPH101 for the Treatment of Sickle Cell Disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to d...

7 months ago - Business Wire

Graphite Bio Announces Participation in the ASGCT 25th Annual Meeting Including Oral Presentation About Beta-thalasse...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to d...

7 months ago - Business Wire

Graphite Bio Announces Participation in H.C. Wainwright Gene Therapy and Gene Editing Virtual Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on developing therapies that harness targeted gene integra...

8 months ago - Business Wire

Graphite Bio Announces Formation of Scientific Advisory Board

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on developing therapies that harness targeted gene integra...

8 months ago - Business Wire

Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2021 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH) reported recent business progress and fourth quarter and fiscal year 2021 financial results.

8 months ago - Business Wire

Graphite Bio Announces Participation in Upcoming Cowen 42nd Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to tre...

9 months ago - Business Wire

Graphite Bio Appoints Alethia Young as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. today announced the appointment of Alethia Young as chief financial officer.

9 months ago - Business Wire

Is a Surprise Coming for Graphite Bio (GRPH) This Earnings Season?

Graphite Bio (GRPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

9 months ago - Zacks Investment Research

SomaLogic, Graphite Bio Make List of Most Promising Life Sciences Companies

Two public companies made the BioSpace list of the 30 most promising North American life sciences startups. SomaLogic Inc. ( SLGC , Financial) and Graphite Bio Inc. ( GRPH , Financial) are included in t...

Other symbols: SLGC
10 months ago - GuruFocus

Graphite Bio Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sic...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $GRPH #ASH21--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene i...

11 months ago - Business Wire

Graphite Bio to Host Key Opinion Leader Webinar on Gene Correction for Sickle Cell Disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to tre...

11 months ago - Business Wire

Graphite Bio Enrolls First Patient in Phase 1/2 Clinical Trial of GPH101 for Sickle Cell Disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $GRPH #GraphiteBio--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted ...

1 year ago - Business Wire